ClinicalTrials.gg
RecruitingNCT04416854Updated Jun 4, 2020

The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer

A Phase 3 interventional study of resection of primary tumor and XELOX in Metastatic Colon Cancer and Surgery, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-04.

Sponsored by Fudan University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Apr 2020; still recruiting 6 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
627
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Colonic Neoplasms by Fudan University — 11 open to participants now, 12 under way, 3 of them phase 3. Colonic Neoplasms · Fudan University.

Planned enrollment
3rd of 16
627 · median 122
Started
2020
the only one that year
Phase 3
3 of 19
3 open now
Primary completion
2023-12
later than 1 of 11 live
Registered
6th of 19
by date

Among the 19 studies in Colonic Neoplasms by Fudan University, this one is the 3rd largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2020, is one of 3 in phase 3, reaches primary completion later than 1 of the 11 other live ones, and was the 6th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

11 of the 19 studies in Colonic Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Colonic Neoplasms by Fudan University, or all of them as a file.
02

Study summary

The aim of this trial is to evaluate the value of palliative primary tumor resection in colon cancer patients with initially unresectable metastases and a positive response to induction chemotherapy which depends on gene testing. The primary endpoint is to evaluate overall survival.

03

Conditions studied

  • Metastatic Colon Cancer
  • Surgery

Browse trials for

Keywords

  • palliative surgery
  • stage IV colon cancer
  • chemotherapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 75 years old
  • (Eastern Cooperative Oncology Group) 0-1 and expected survival period for 6 months or more
  • Pathological diagnosis of colon cancer adenocarcinoma
  • At least one measurable objective tumor lesions which could be evaluated.
  • Primary and tumors exist at the same time, and distant metastases are not resectable
  • ≥1.5*109/L;≥90*109/L;HB≥90g/L;TBI≤1.5(UNL); 、AST≤2.5ULN;Cr≤1.0() screening within 7 days
  • No systemic chemotherapy
  • Patients with voluntary participation, and sign the

Exclusion criteria

Exclusion Criteria:

  • Operation intervention required for perforation, bleeding and obstruction of intestinal cavity
  • Multiple primary colorectal carcinoma
  • Malignant peritoneal effusion or carcinoma of the peritoneum
  • Uncontrolled pleural effusion
  • Malignant tumour of the past five years with other organizations to source, but the full treatment of cervical carcinoma in situ and except skin basal cell carcinoma and squamous cell carcinomas
  • With or meningeal metastasis
  • Pregnancy or breast-feeding women
  • Alcohol or drug addictions
  • There is an important organ failure or other serious diseases, including coronary artery disease, symptomatic cardiovascular disease or myocardial infarction within 12 months; serious neurological or psychiatric history; severe infection; actively disseminated vascula blood coagulation
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
627 participants (estimated)

Study arms

  • Experimental
    Chemotherapy plus surgery

    Chemotherapy plus surgery: Four cycles of XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy accroding to gene testing. After 4 cycles, the patients are randomized to surgery group. Patients receive palliative resection of Primary tumor. Then the rest four cycles XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy are administrated.

    Procedure: resection of primary tumor · Drug: XELOX · Drug: mFOLFOX6

  • Active comparator
    Chemotherapy alone

    Chemotherapy alone: Four cycles of XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy accroding to gene testing. After 4 cycles, the patients are randomized to chemotherapy group. The rest four cycles XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy are administrated.

    Drug: XELOX · Drug: mFOLFOX6

Interventions

  • Procedureresection of primary tumor

    resection of primary lesion with unresectablely metastatic colon cancer

  • DrugXELOX

    Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle

  • DrugmFOLFOX6

    Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1,2400 mg/m2 CIV 46h, d1

06

What researchers measure

Primary outcomes

  1. Overall survival

    Time frame: 5-year

Secondary outcomes

  1. Progression-free survival 1

    The first progression time after diagnosis

    Time frame: 3-year

  2. Progression-free survival 2

    The first progression time after randomization

    Time frame: 3-year

  3. The rate of adverse events resulted from chemotherapy

    The ratio of the number of patients experienced adverse events to the total patients

    Time frame: 3-year

  4. The quality of life postoperatively

    The European Organization for Research and Treatment (EORTC)-QLQ-C30 HRQL questionnaire was assessed with repeated measures at regular intervals postoperatively at months 3, 6, 9, 12, 18, and 24

    Time frame: 3-month, 6-month, 9-month, 12-month, 18-month, 24-month

  5. Objective response rate

    Time frame: 1-year

  6. The rate of postoperative complications

    The ratio of the number of patients with postoperative complications to the total patients

    Time frame: 1-year

  7. The proportion of surgical intervention in control group

    Time frame: 1-year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2020 (actual). Primary completion is estimated for Dec 2023, 44 months after the start.

Of 55 non-industry phase 3 interventional studies under Colonic Neoplasms, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 123. This study's planned 44 months is below that.

Counting every sponsor, half of 72 studies reached it within 55 months; a quarter within 37 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2020
First posted
Jun 4, 2020
StartActual
Apr 1, 2020
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2025
Last update
Jun 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04416854
Lead sponsor
Fudan University
Responsible party
LI XIN-XIANG (Professor, Fudan University) — Principal investigator
First posted
Jun 4, 2020
Start date
Apr 1, 2020
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jun 4, 2020

Study contacts

Xinxiang Li
Contact
1149lxx@sina.com
+8613761291659
Qingguo Li
Contact
qingguoli@fudan.edu.cn
+8618918298120

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion